We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $52.25 · 8 analysts
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages MarketBeat
Kyle Carver Increases Stake in Evommune Inc with Recent Share Pu - GuruFocus
Kyle Carver Increases Stake in Evommune Inc with Recent Share Pu GuruFocus
Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock - MarketBeat
Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock MarketBeat
Independent Director of Evommune Arthur Kirsch Buys More Stock - simplywall.st
Independent Director of Evommune Arthur Kirsch Buys More Stock simplywall.st
Form 4 Evommune Inc For: 8 July By Investing.com - Investing.com South Africa
Form 4 Evommune Inc For: 8 July By Investing.com Investing.com South Africa
EVMN stock tanks as Phase IIb urticaria study misses primary goal - MSN
EVMN stock tanks as Phase IIb urticaria study misses primary goal MSN
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.67 | — | — | $1.03M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-9.48 | — | — | $3M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-30.69 | — | — | $7M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 26. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 12. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 04. 10. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 03. 18. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 03. 18. | Clear Street | — | Initiate coverage | — → Buy | — | Clear Street: Buy |
| 2026. 02. 11. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 36,577 | $840.91K | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 34,384 | $588.65K | 0.00% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 21,324 | $365.07K | 0.00% | — | New position |